CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
Not yet recruiting · NCT06647329 · Registry updated 2024-10-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 1 | 2024-10-17 | NCT06647329 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mingzhi Zhang | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| the First Hospital of Zhengzhou University | Zhengzhou | China | 1 |